Skip to main content
. 2020 Jan 22;10:964. doi: 10.1038/s41598-020-57799-w

Figure 4.

Figure 4

Case study comparison of (weighted) k-NN and bootstrap matching for (a) bevacizumab (2784 treated patients), (b) cetuximab (845 treated patients), (c) panitumumab (308 treated patients), and (d) aflibercept (31 treated patients). Shown are the number of SG outcomes being censored (top), the mean subject-specific treatment-effect (STE) variance (middle) and the variance of the STE variance (bottom).